16:53 GMT19 September 2020
Listen Live
    Get short URL
    Global COVID-19 Cases Spike to Highest Level Post-Lockdown (157)

    Remdesivir is one of the few medicines that has so-far proven to be effective in mitigating severe cases of the coronavirus infection, despite originally being developed by Gilead as a treatment for Hepatitis C.

    The European Union Commission has announced the signing of a deal with the American firm Gilead Sciences to secure access to its anti-coronavirus drug, Remdesivir. The deal would provide treatment against COVID-19 for around 30,000 patients across the bloc, as well as the UK, which is in the process of withdrawing from it.

    "The Commission signed a contract […] for ensuring treatment doses of Veklury - the brand name for Remdesivir. As of early August onwards, batches of this medicine Veklury will be made available to member states and the UK", spokeswoman for the European Commission, Dana Spinant, said.

    The EU Commission spokeswoman went on to note that the first batch of the 63-million euro ($73.99 million) contract will be used to address the union’s immediate needs. She added that member states are currently working to ensure additional procurements of the drug starting in October without revealing how many doses will be ordered in the next deal.

    Remdesivir was originally designed by Gilead Sciences as a treatment for patients suffering from Hepatitis C, but it was authorised for emergency use in severe coronavirus cases after some studies suggested it might shorten the time needed for a person to recover from the infection.

    A study conducted by the US National Institutes of Health showed that Remdesivir shortened the recovery time from an average of 15 days to 11 days, although the authors of the study admitted that the medication alone is not sufficient to treat a person suffering from COVID-19. At the same time, a competing study of the drug in China showed contrary results indicating that the medicine not only had little positive influence on the patients, but also resulted in various adverse side-effects.

    Global COVID-19 Cases Spike to Highest Level Post-Lockdown (157)


    Remdesivir Reduces Mortality Risk in Severely Ill COVID-19 Patients, New Analysis Finds
    Gilead Plans to Charge Over $3,000 for COVID-19 Antiviral Remdesivir
    'Nothing For Europe': Expert Raises Alarm as US Buys Almost All Remdesivir Stock
    EU in Talks With Gilead to Secure Remdesivir After US Bought Up Supply
    Remdesivir May Be Lifesaving for COVID-19 Patients, Yet Toxic for US-EU Relations
    EU Greenlights Use of Remdesivir to Treat COVID-19
    medicine, coronavirus, COVID-19, US, EU
    Community standardsDiscussion